Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 99   

Articles published

CBST 66.40 -0.94 (-1.40%)
price chart
New Cubist Pharmaceuticals chief executive will be Robert J. Perez
Cubist Pharmaceuticals Inc. said Monday it plans to install a new chief executive, a surprise move that raised questions about whether the Lexington company will keep expanding as the leading US maker of antibiotics or become a takeover target.
Cubist To Report 2014 Fiscal Third Quarter Results Today  Bidness ETC
Cubist says Michael Bonney will retire as CEO; company will promote ...  Daily Journal
Related articles »  
Cubist Pharmaceuticals Inc.: Cubist Reports Third Quarter 2014 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the third quarter ended September 30, 2014.
Cubist Pharmaceuticals (CBST) Announces Quarterly Earnings, Beats Estimates ...  Mideast Time
Cubist Pharma Turns To Profit In Q3, Results Beat View  RTT News
Related articles »  
Stocks Alert: Energy XXI (Bermuda) Limited (NASDAQ:EXXI), Ohr ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) said its president and chief operating officer Robert J. Perez will take over as Chief Executive Officer, effective January 1, 2015, replacing Michael Bonney who is retiring.
Related articles »  
Technical Data on Biotech Equities - Intrexon, Keryx Biopharma, Spectrum ...
Investor-Edge has initiated coverage on the following equities: Intrexon Corporation (NYSE: XON), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Cubist ...
Related articles »  
Cubist Pharma Reports Q3 Non-GAAP EPS Of $0.58 - Quick Facts
Cubist Pharmaceuticals Inc. (CBST: Quote) reported third-quarter net income of $22.83 million or $0.29 per share, compared to a loss of $33.90 million or $0.50 per share, previous year.
Cubist Pharmaceuticals EVP Unloads $3146894 in Stock (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) EVP Steven C. Gilman sold 48,125 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $65.39, for a total ...
Related articles »  
Watch List -Dicks Sporting Goods Inc (NYSE:DKS),Cubist Pharmaceuticals Inc ...
Manhattan, NY- October 21, 2014 - (Techsonian) - Dicks Sporting Goods Inc (NYSE:DKS) the largest U.S. based full-line omni-channel sporting goods retailer, will be opening its 37th store in California and 594th store nationwide on Friday, October 31st ...
Morningstar Assigns BBB- Credit Rating to Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has received a �BBB-� credit rating from analysts at Morningstar.
News Round Up- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cubist ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) recently declared that the U.S. Food and Drug Administration have granted Breakthrough Therapy designation to NUPLAZID for the treatment of Parkinson's disease psychosis.
Related articles »  
Morningstar Gives "BBB-" Credit Rating to Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has been given a �BBB-� credit rating by Morningstar.
Stocks to Track �Cubist Pharmaceuticals Inc (NASDAQ:CBST), ManpowerGroup ...  Techsonian (press release)
Related articles »